Alphabet (GOOGL) slips after hours despite Street-beating Q2 >>> READ MORE

TEVA

Is Teva Pharmaceutical Industries Ltd (ADR) Stock a Migraine Buy?

Teva's recent migraine drug data, while positive, didn't impress investors. What happened, and should you tussle with TEVA stock? More 

How Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Recover

Teva Pharmaceutical desperately needs a new CEO - and a new strategy to boot - to stop the steady decline in TEVA stock. More 

Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Gain 30%

Teva (TEVA) has been unfairly beat down, but its near-5% dividend yield makes TEVA stock worthwhile while waiting on the recovery. More 

3 Naked Puts for $1,000 in Summertime Cash

Use these three naked put options to generate $1,000-plus in cash, or lower the effective purchase price of a stock. More 

Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Going to $40

Teva Pharmaceutical (TEVA) offers good value, especially when combined with its 4.49% annual dividend yield. Here's how TEVA stock is heading to $40. More 

Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Recover

TEVA stock has been slammed with poor news and fierce competition, but with a little luck, Teva Pharmaceuticals could be a big play in 2017. More 

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Bounce Now

Teva Pharmaceutical's first-quarter earnings and reaffirmed guidance are good enough, and should at least drive a relief rally in TEVA stock. More